Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ketone-based Therapy
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Recipient : Selah Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Details : The company will focus on developing first-in-class novel ketone-based therapies for chronic diseases of aging of which our first therapeutic focus is heart disease with secondary interests in neurological diseases.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 11, 2022
Lead Product(s) : Ketone-based Therapy
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Recipient : Selah Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : LYG-LIV0001
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Recipient : Lygenesis
Deal Size : $11.0 million
Deal Type : Financing
Details : Proceeds will be used to fund LyGenesis’s Phase 2a clinical trial with a first patient in targeted for early 2021, also to push forward on their other cell therapies using lymph nodes as bioreactors to regrow functioning organs.
Brand Name : LYG-LIV0001
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 30, 2020
Lead Product(s) : LYG-LIV0001
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Recipient : Lygenesis
Deal Size : $11.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?
Reset All
